MEKICS Co Ltd (058110) Fair Value & Analysis
Healthcare · KR · Market cap 27.5B KRW
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 6 days ago
Fair value updated Aug 13, 2026, revised from 1,584 KRW to 1,581 KRW (−0.2%) since Jul 22, 2026. Share price −1.4% over the past month.
Below-average quality, and screening another 11% overvalued on our models.
What matters now
- A fairly wide model range (1,180 KRW to 2,360 KRW) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 1,486 KRW – 18,125 KRW · fair‑value band 1,180 KRW – 2,360 KRW · the 1,784 KRW price screens above the 1,581 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
MEKICS Co Ltd (058110) currently trades at 1,784 KRW, while our model-based Fair Value estimate is 1,581 KRW, implying the stock looks roughly 11.4% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, MEKICS Co Ltd generated revenue of 33.2B KRW at a net margin of 3.2%. Revenue declined 56.3% year over year. Net debt stands at 12.5B KRW. Fundamentals as of Aug 13, 2026
Our scenario range runs from 1,180 KRW (bear case) to 2,360 KRW (bull case); at 1,784 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 55% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -11%, 058110 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 058110 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 28
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
MEKICS CO., Ltd develops and commercializes ventilators worldwide. It offers general-purpose ventilators, respiratory care devices, patient monitoring systems, pulse oximeter, central monitoring system, and high flow nasal therapy products. The company also distributes CPAP solutions that care sleep apnea syndrome and snoring.
Full company description
MEKICS CO., Ltd develops and commercializes ventilators worldwide. It offers general-purpose ventilators, respiratory care devices, patient monitoring systems, pulse oximeter, central monitoring system, and high flow nasal therapy products. The company also distributes CPAP solutions that care sleep apnea syndrome and snoring. MEKICS CO., Ltd was founded in 1998 and is headquartered in Paju, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
MEKICS Co Ltd reported revenue of 11.3B KRW in FY2025 versus 49.3B KRW in FY2021, a compound −30.8%/yr. Reported net income was −2.5B KRW in FY2025.
058110 screens 11% overvalued. Compare with InBody Co →
Peer Group
Health Care · 2296 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| InBody Co 041830 | 67,400 KRW | 49,984 KRW | -26% |
| i-SENS, Inc 099190 | 18,480 KRW | 8,168 KRW | -56% |
| Value Added Technology Co 043150 | 20,950 KRW | 60,242 KRW | +188% |
| Mediana Co 041920 | 10,070 KRW | 6,289 KRW | -38% |
| Meta Biomed Co 059210 | 3,980 KRW | 9,268 KRW | +133% |
| Sewoon Medical Co 100700 | 2,300 KRW | 6,054 KRW | +163% |
| CU Medical Systems, Inc 115480 | 2,195 KRW | 1,134 KRW | -48% |
| PeopleBio, Inc 304840 | 561.00 KRW | 504.98 KRW | -10% |
| Novartis AG NVSN | 2,742 MXN | 1,964 MXN | -28% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
Compare MEKICS Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is MEKICS Co Ltd (058110) overvalued or undervalued?
What is the fair value of 058110?
What is the quality score of 058110?
What is the revenue of MEKICS Co Ltd (058110)?
What is the net profit margin of 058110?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track MEKICS Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.